Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List

2024-04-10
|
Page View:

On March 22, the 2024 Shanghai Industrial Technology Innovation Conference was held with the theme of "Building the Main Engine of Innovation and Seizing New Opportunities in the Future".  At this conference, Medicilon won the "2024 Shanghai Hard Core Technology Enterprises TOP100 List" with its hard-core technology and innovative technology service platform in the preclinical field of biopharmaceutical.

Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List.webp

As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon has always been committed to exploring hard-core technologies in the biopharmaceutical preclinical field.  After 20 years of development, Medicilon now has 84,000 square meters of R&D laboratories and a high-quality R&D team.  Through continuous technological innovation and R&D investment, we have conquered the core R&D technologies of new molecular types of drugs such as antibodies, peptides, ADCs, PROTACs, mRNA vaccines, small nucleic acid drugs, cell & gene therapy (CGT), and established a R&D service platform to empower and accelerate global pharmaceutical innovation.  At the same time, Medicilon also has a wealth of innovative drug molecule design technology, relying on computer-aided drug design technology, high-throughput drug discovery technology, and bioelectronic isostere technology to establish a more efficient AI-guided drug design and synthesis platform to help clients improve R&D efficiency and reduce R&D barriers.

It is these hard-core scientific and technological innovation capabilities that have enabled Medicilon to empower 421 IND-approved clinical trials in the biopharmaceutical preclinical field, winning widespread recognition and praise, and attracting the favor of many partners.  Looking forward to the future, Medicilon will continue to stride forward on the journey of technological innovation and industrial development, injecting continuous innovative vitality and power into the global biopharmaceutical industry!

Return
Relevant newsRelevant news